SELLAS Life Sciences Stock Jumps 13% on Executive Severance Changes, Sparking Buyout Speculation

According to a Securities and Exchange Commission filing disclosed on Tuesday, SELLAS Life Sciences Group, Inc. (SLS) shares jumped nearly 13% on Thursday after the biopharmaceutical company announced updates to severance arrangements for its top three executives. The changes, which took effect immediately, provide enhanced protection in case of a change in control, fueling renewed speculation of a potential acquisition.

CEO Dr. Angelos Stergiou's agreement was amended to allow change-in-control severance payments as a lump sum rather than over time. CFO John Burns and Chief Development Officer Dragan Cicic each entered into new severance agreements offering 15 months of base salary plus full target annual bonus in the event of termination linked to a change of control, with accelerated vesting of all unvested equity awards.